Vaccine Production and R&D with Corning Solutions - A New Approach
: 24 Apr 2020
Sector: Clinical, Pharmaceutical
Date: 3pm (GMT) on the 24th of April 2020
Vaccines are considered to be one of the biggest public health achievements of the past century, and the concept of stimulating the organism’s immune response is the basis underlying vaccination. Vaccines act by initiating the innate immune response when activating antigen-presenting cells, inducing a protective response towards a pathogen.
These agents may contain live-attenuated, inactivated, or only parts of a pathogen. In this context, Corning provides a diverse set of single-use products for upstream vaccine manufacturing needs. As scale-up progresses, vessels and surfaces constantly increase in space efficacy, reducing the cost and minimizing the labor per titer.
This presentation aims to provide background information about the main forms of vaccine designs, R&D and manufacturing workflows, and updated data generated in Corning’s application labs.
Presenter Bio: After graduating from Biochemistry in the University of Santiago (Chile), Constanza pursued directly a career in the Chilean Vaccine R&D industry, developing as a bioprocess scientist for both bacterial and viral vaccines in the field of animal health, being in charge of scale-up, and tech transfer with manufacturing plants.
She further developed her career in Belgium as a bioprocess scientist, this time in the field of recombinant protein production, pursuing protocol optimization and scale-up experiments with suspension mammalian cell lines. Constanza is currently a field applications scientist in Corning for the EMEA region, providing customers with in-depth technical support, presenting seminars and training, and assisting customers in experimental set-up and troubleshooting.